126 related articles for article (PubMed ID: 8138560)
21. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
Gekeler V; Boer R; Uberall F; Ise W; Schubert C; Utz I; Hofmann J; Sanders KH; Schächtele C; Klemm K; Grunicke H
Br J Cancer; 1996 Sep; 74(6):897-905. PubMed ID: 8826855
[TBL] [Abstract][Full Text] [Related]
22. [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism.
MacKinnon AC; Armstrong RA; Waters CM; Cummings J; Smyth JF; Haslett C; Sethi T
Br J Cancer; 1999 Jun; 80(7):1026-34. PubMed ID: 10362111
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy of lung cancer.
Marsh JC
Conn Med; 1975 May; 39(5):283-4. PubMed ID: 165035
[No Abstract] [Full Text] [Related]
24. Comparison of ability of protein kinase C inhibitors to arrest cell growth and to alter cellular protein kinase C localisation.
Courage C; Budworth J; Gescher A
Br J Cancer; 1995 Apr; 71(4):697-704. PubMed ID: 7710931
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
[TBL] [Abstract][Full Text] [Related]
26. Expression of Ca2+/calmodulin-dependent protein kinase types II and IV, and reduced DNA synthesis due to the Ca2+/calmodulin-dependent protein kinase inhibitor KN-62 (1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenyl piperazine) in small cell lung carcinoma.
Williams CL; Phelps SH; Porter RA
Biochem Pharmacol; 1996 Mar; 51(5):707-15. PubMed ID: 8615909
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of protein kinase C epsilon protein in lung cancer cell lines by ionising radiation.
Kim CY; Giaccia AJ; Strulovici B; Brown JM
Br J Cancer; 1992 Nov; 66(5):844-9. PubMed ID: 1329908
[TBL] [Abstract][Full Text] [Related]
28. Properties of classic protein kinase C in human small cell lung carcinoma NCI-H345 cells.
Jones CL; Beck LK; Brozna JP; Holley M; Dempsey EJ; Kane MA
Cell Growth Differ; 1995 Dec; 6(12):1627-34. PubMed ID: 9019168
[TBL] [Abstract][Full Text] [Related]
29. [nm23-H1 gene inhibits lung cancer cell invasion through down-regulation of PKC signal pathway].
Nie Q; Zhou QH; Zhu W; Liu LX; Fu JK; Li DB; Li Y; Che GW
Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):334-6. PubMed ID: 17044994
[TBL] [Abstract][Full Text] [Related]
30. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.
Forest F; Yvorel V; Karpathiou G; Stachowicz ML; Vergnon JM; Fournel P; Tiffet O; Trombert B; Péoc'h M
Hum Pathol; 2016 Mar; 49():99-106. PubMed ID: 26826416
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy of carcinoma of the lung.
Block JB
Curr Probl Cancer; 1977 Apr; 1(10):40-7. PubMed ID: 198182
[No Abstract] [Full Text] [Related]
32. In vivo reversibility of multidrug resistance by the MDR-modulator dexniguldipine (niguldipine derivative B859-35) and by verapamil.
Dietel M; Boss H; Reymann A; Pest S; Seidel A
J Exp Ther Oncol; 1996 Jan; 1(1):23-9. PubMed ID: 9414385
[TBL] [Abstract][Full Text] [Related]
33. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
[TBL] [Abstract][Full Text] [Related]
34. Molecular Studies on Novel Antitumor Bis 1,4-Dihydropyridine Derivatives Against Lung Carcinoma and their Limited Side Effects on Normal Melanocytes.
Mohamed MF; Ibrahim NS; Elwahy AHM; Abdelhamid IA
Anticancer Agents Med Chem; 2018; 18(15):2156-2168. PubMed ID: 30338746
[TBL] [Abstract][Full Text] [Related]
35. [Update of human tumor clonogenic assay in carcinoma of the lung].
Kanzawa F
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1552-9. PubMed ID: 2992395
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the dexniguldipine binding site in the multidrug resistance-related transport protein P-glycoprotein by photoaffinity labeling and mass spectrometry.
Borchers C; Boer R; Klemm K; Figala V; Denzinger T; Ulrich WR; Haas S; Ise W; Gekeler V; Przybylski M
Mol Pharmacol; 2002 Jun; 61(6):1366-76. PubMed ID: 12021398
[TBL] [Abstract][Full Text] [Related]
37. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
Ohlmann CH; Jung C; Jaques G
Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
[TBL] [Abstract][Full Text] [Related]
38. Morphine Suppresses Lung Cancer Cell Proliferation Through the Interaction with Opioid Growth Factor Receptor: An In Vitro and Human Lung Tissue Study.
Kim JY; Ahn HJ; Kim JK; Kim J; Lee SH; Chae HB
Anesth Analg; 2016 Dec; 123(6):1429-1436. PubMed ID: 27167686
[TBL] [Abstract][Full Text] [Related]
39. Influence of dexniguldipine-HC1 on rhodamine-123 accumulation in a multidrug-resistant leukaemia cell line: comparison with other chemosensitisers.
Boer R; Haas S; Schödl A
Eur J Cancer; 1994; 30A(8):1117-23. PubMed ID: 7654442
[TBL] [Abstract][Full Text] [Related]
40. Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells.
Malkhandi J; Ferry DR; Boer R; Gekeler V; Ise W; Kerr DJ
Eur J Pharmacol; 1994 Dec; 288(1):105-14. PubMed ID: 7705462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
